534 Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 ≥50% treated with first line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry

• DOI: 10.1136/jitc-2024-sitc2024.0534
• Publication Date: 2024-11-05T14:58:58Z
• Authors: Alessio Cortellini; Edoardo Garbo; Leonardo Brunetti; Giuseppina Rita D...; Monica Loza; Carlo Genova; Ritujith Jayakris...; Michele Montrone; Mingjia Li; Lauren Young; Giulio Metro; Francesco Passiglia; Nichola O Awosika; Eleni Josephides; Bartlomiej Tomasik; Raffaele Giusti; Emilio Bria; Maximilian Rost; Gabriele Minuti; Francesca Mazzoni; Avinash Aujayeb; Alessandro Morabito; Alessandro Leonetti; Alfredo Addeo; Giannis Mountzios; Sukumar Kalvapudi; Eleni Karapanagiotou; Isabelle Monnet; Aida Piedra; Francesco Agustoni; Diego L Cortinovis; Teresa Gorria; Teresa Beninato; Laura Moliner; Federica Biello; Taher A Hejleh; Amin Nassar; Biagio Ricciuti